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Apical membrane antigen 1 (AMA-1) is a leading blood-stage malaria vaccine candidate. Consistent with a key role in erythro-
cytic invasion, AMA-1-specific antibodies have been implicated in AMA-1-induced protective immunity. AMA-1 is also ex-
pressed in sporozoites and in mature liver schizonts where it may be a target of protective cell-mediated immunity. Here, we
demonstrate for the first time that immunization with AMA-1 can induce sterile infection-blocking immunity against Plasmo-
dium sporozoite challenge in 80% of immunized mice. Significantly higher levels of gamma interferon (IFN-)/interleukin-2
(IL-2)/tumor necrosis factor (TNF) multifunctional T cells were noted in immunized mice than in control mice. We also report
the first identification of minimal CD8 and CD4 T cell epitopes on Plasmodium yoelii AMA-1. These data establish AMA-1 as
a target of both preerythrocytic- and erythrocytic-stage protective immune responses and validate vaccine approaches designed
to induce both cellular and humoral immunity.
The Plasmodium apical membrane antigen-1 (AMA-1) is anintegral membrane protein which is essential for the develop-
ment of apicomplexan parasites in their host environment (1).
The AMA-1 mRNA half-life peaks in blood-stage trophozoites,
and expression of AMA-1 protein is maximized in the late asexual
schizont stage (www.plasmoDB.org) (2). Although it is structur-
ally conserved across apicomplexa, some domains of AMA-1
show high levels of amino acid polymorphism (3). It is thought
that the host immune response provides the predominant selec-
tive pressure for these interstrain variations, with the parasite
varying key targets to evade host immunity (1).
Upon contact with the host cell, the 83-kDa AMA-1 protein is
proteolytically processed into its 66-kDa mature form, which is
transported to the cell surface membrane (4). In blood-stage
merozoites, AMA-1 is concentrated at the apical pole and poten-
tially participates in the reorientation and attachment of merozo-
ites to red blood cells (RBC) (5, 6). Recently, a direct interaction
between AMA-1 on the merozoite surface and the rhoptry neck
protein (RON) complex inserted into the RBC membrane prior to
invasion has been described (7, 8). This AMA-1–RON complex is
conserved in apicomplexans, suggesting functional importance
for host cell invasion (6, 9). Upon cell entry, the AMA-1 ectodo-
main is shed; this process appears to be essential for invasion, since
antibodies that inhibit shedding also inhibit invasion (1). The re-
maining cytoplasmic AMA-1 tail plays an essential role in trigger-
ing and maintaining intracellular replication of the parasite,
which is distinct from its role in invasion of RBC, but the exact
function of AMA-1 remains unknown (10–12).
The mechanisms of protection against malaria are also not
completely understood, but they include the generation of a hu-
moral response that blocks parasite entry into host cells and in-
hibits intracellular parasite growth, as well as the induction of
parasite-targeted cellular immune responses that directly and in-
directly promote the killing of intracellular parasites and mediate
protection from reinfection (13–17).
Studies have shown that immunization with correctly folded,
parasite-derived or heterogeneously expressed AMA-1 protein
can protect against blood-stage parasite challenge in rodent (P.
berghei, P. yoelii, or P. chabaudi) and nonhuman primate (P.
knowlesi) models (1, 18–25). Additionally, AMA-1-induced pro-
tection has been associated with species-specific invasion and
growth-inhibiting antibodies against AMA-1, providing protec-
tion upon passive transfer in mice (21). In humans naturally ex-
posed to malaria, there is a high prevalence of AMA-1 antibodies,
with titers correlating to age (26, 27). Accordingly, efforts to de-
velop an AMA-1-based vaccine have focused on the induction of
persistent, high-titer antibody responses and have almost exclu-
sively used recombinant proteins formulated in various adjuvants
(1, 22, 24, 26, 28, 29). However, although strong antibody re-
sponses and in vitro functionality have been reported in some
studies, AMA-1-based vaccines have failed to confer significant
protection in humans (30–33). There is evidence that AMA-1-
specific CD4 T cells may play a role in blood-stage immunity,
since the efficacy of AMA-1 immunization depends on the pres-
ence of CD4 T cells and adoptive transfer of AMA-1 specific
CD4 T cell lines could protect nude mice against parasitized red
blood cell (pRBC) challenge (34–37). Furthermore, blood-stage
vaccine trials of AMA-1 as a protein/adjuvant formulation have
reportedly elicited T cell responses producing a number of cyto-
kines, including interleukin-5 (IL-5), IL-2, and gamma interferon
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(IFN-), as well as multifunctional CD4 cytokine-producing T
cells and memory T cells (38–41).
Expression of AMA-1 has been described in sporozoite and
both early and late liver stages in addition to asexual blood stages
(4, 42, 43). A role for AMA-1 in sporozoite invasion has been
suggested (4), but it was recently demonstrated that while AMA-1
might mediate host cell recognition as well as parasite orientation
and stabilization of hepatocyte binding, it is not essential for in-
vasion and differentiation inside hepatocytes (44). The presence
of AMA-1 in the sporozoite and liver stages suggests that it may be
a potential target of preerythrocytic-stage immunity. However,
although AMA-1 has been extensively studied as a candidate an-
tigen for asexual erythrocytic malaria vaccines, information on its
role in preerythrocytic immunity is scarce. There are numerous
data sets showing that AMA-1 is recognized by antibodies from
malaria-naive individuals immunized with radiation-attenuated
sporozoites which do not develop into mature liver schizonts (45)
as determined by enzyme-linked immunosorbent assay (ELISA),
indirect fluorescent-antibody tests (IFATs) (J. Sacci, personal
communication), and protein microarray studies (46). Those data
show that AMA-1 is accessible to the immune system during early
liver-stage development. However, to our knowledge, there are no
reports demonstrating that AMA-1 vaccines can protect against
Plasmodium sporozoite challenge in the absence of other Plasmo-
dium antigens. Several studies in mice, nonhuman primates, and
humans have investigated the protective capacity of multiantigen
vaccines against sporozoite challenge, with no conclusive results.
In the P. knowlesi nonhuman primate model, DNA prime/poxvi-
rus boost immunization with a combination of four candidate
vaccine antigens, i.e., circumsporozoite protein (CSP), sporozoite
surface protein 2 (SSP2), AMA-1, and the 42-kDa fragment of
merozoite surface protein 1 (MSP142), led to self-limited, low-
level parasitemia in 60% to 80% of rhesus monkeys (47, 48). In
humans, a virosome-based vaccine comprising peptides repre-
senting the P. falciparum CSP B cell repeat and the semiconserved
loop I of domain III of AMA-1 induced very limited blood-stage
protection (manifested primarily as a delay in development of
parasitemia in 1 of 12 volunteers) (49). However, in both studies,
protective effects could not explicitly be associated with defined
immune responses to any one or all target antigens. Most recently,
a two-component adenovirus-vectored vaccine consisting of one
adenovector encoding the P. falciparum CSP protein and one en-
coding AMA-1 induced moderate T cell IFN- responses against
both antigens but only low antibody responses, with no growth-
inhibitory activity. However, the protective efficacy of the combi-
nation or of the AMA-1 component alone was not assessed (50).
Here, we report the first study to investigate the true potential
of AMA-1 as a preerythrocytic-stage vaccine candidate. With this
goal, we have employed two parallel strategies that target cellular
immune responses against P. yoelii AMA-1 (PyAMA-1) using
both a DNA prime/protein boost regimen and a T cell epitope/
adjuvant immunization approach.
MATERIALS AND METHODS
Mice and parasites. Specific-pathogen-free female BALB/c mice (Animal
Resource Centre, Perth, Australia) were immunized at 6 weeks of age. The
parasite strain used in all experiments was Plasmodium yoelii 17XNL.
Cryopreserved sporozoites kindly provided by Stephen Hoffman (Sanaria
Inc., Rockville, MD, USA) were used for sporozoite challenge. Parasitized
red blood cells (pRBC) used for blood-stage challenge were obtained after
one passage of frozen pRBC stock (derived from cryopreserved sporozo-
ites at 14 days postinfection) through a BALB/c mouse. All studies were
approved by the QIMR Animal Ethics Committee and were conducted in
accordance with the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes (2004).
Parasite extract. P. yoelii extract was generated from P. yoelii 17XNL
grown in BALB/c mice to approximately 50% parasitemia. Blood was
collected by cardiac puncture and diluted with 10 volumes of FCAB (flow
cytometric assessment of blood) buffer (1 phosphate-buffered saline
[PBS], 0.5% fetal calf serum [FCS], 2 mM EDTA) (51). The blood sample
was centrifuged at 600 relative centrifugal force (RCF) for 10 min, and the
cell pellet was resuspended in 0.5% (wt/vol) saponin (Sigma-Aldrich, Cas-
tle Hill, NSW, Australia) in FCAB buffer and incubated for 30 min at
37°C. The sample was then twice drawn through a 30-gauge needle,
washed with 20 volumes of Milli-Q H2O, and centrifuged as described
above. pRBC were fixed in FCAB fixation and lysis buffer (1 PBS, 4%
[wt/vol] paraformaldehyde, and 0.0067% [wt/vol] saponin) for 10 min
at 37°C. The extract was resuspended in FCAB buffer and stored at
20°C prior to use. All buffers were sterile filtered (0.2 m) immedi-
ately before use.
Synthetic peptides. Putative PyAMA-1 CD4 and CD8 T cell
epitopes were predicted from the complete PyAMA-1 protein sequence
(www.plasmoDB.org) (52, 53) using computerized major histocompati-
bility complex (MHC) binding prediction algorithms available from the
Immune Epitope Data Base (www.IEDB.org) (54). Peptides were selected
for MHC alleles expressed by BALB/c mice (MHC class I, H-2Kd and
H-2Dd; MHC class II, IAd and IEd). A consensus algorithm approach was
chosen to rank predicted peptides according to their scores from various
prediction methods (ANN, SMM, and Comblib). The top scoring MHC
class I (9-mer; n 15) and MHC class II (15-mer; n 5) nonoverlapping
peptides predicted to bind with highest affinity were selected for study (see
Table S1 in the supplemental material). Peptides were synthesized by
Mimotopes Pty Ltd. (Clayton, VIC, Australia) at a purity of80%, resus-
pended at 50 mg/ml in 100% dimethyl sulfoxide (DMSO), and stored at
80°C prior to use. A pool of all putative CD8 and CD4T cell epitopes
was used to immunize mice.
Plasmid DNA and recombinant protein immunogens. P. yoelii
17XNL genomic DNA (gDNA) was extracted from pRBC of BALB/c mice
14 days after infection withP. yoelii 17XNL sporozoites. PyAMA-1 specific
primers were designed to amplify the full-length gene based on the anno-
tated protein sequence (www.plasmoDB.org) using Amplify 3.1 (http:
//engels.genetics.wisc.edu/amplify/; Bill Engels, University of Wisconsin)
and OligoCalc (www.basic.northwestern.edu/biotools/oligocalc.html)
software tools. Oligonucleotides were commercially synthesized by Sigma-
Aldrich (Castle Hill, NSW, Australia). Full-length PyAMA-1 was cloned
into pVR1020 (Vical, Inc., San Diego, CA), amplified in Escherichia coli
DH5, and purified using an endotoxin-free plasmid extraction kit
(EndoFree Plasmid Giga kit; Qiagen Pty Ltd., Chadstone Centre, VIC,
Australia).
For protein expression, a custom pIVEX-HIS/HA vector was created
by modifying the pIVEX-HIS 3.2 vector (Roche Applied Science, Castle
Hill, NSW, Australia) to express a C-terminal hemagglutinin (HA) tag
(55). The cell-free protein expression system RTS 500 HY E. coli (5 Prime
GmbH, Hamburg, Germany) was used to produce recombinant protein,
which was then His purified using Cobalt Talon resin (Clontech Labora-
tories, Inc., Mountain View, CA). Briefly, Talon resin was equilibrated
with wash buffer (20 mM sodium phosphate, 500 mM NaCl, 10 mM
imidazole) and incubated for 30 min at 4°C with the RTS product solution
in wash buffer containing 8 M urea. The mixture was then transferred to
an Econo-Pac chromatography column (Bio-Rad Laboratories, Glades-
ville, NSW, Australia), the endotoxin was removed with wash buffer con-
taining 0.05% Triton X-114, and the purified protein was eluted with 150
mM imidazole. To exchange the elution buffer with PBS, the protein
eluate was loaded onto a 4-ml 3K Amicon Ultra Filtration tube (Merck
Millipore, Billerica, MA) and concentrated in three alternating spinning
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and washing steps. The protein concentration after the final centrifuga-
tion step was measured using a NanoDrop spectrometer (Thermo Fisher
Scientific) with an A260/A280 ratio of 0.6 (A260/A280 ratios of 	1.8 are
indicative of low nucleic acid contamination, and a value of 0.6 is charac-
teristic of pure protein). The endotoxin level of the purified protein was
assessed by endpoint chromogenic Limulus amoebocyte lysate (LAL) as-
say (QCL-1000, Lonza Group, Basel, Switzerland) and ranged between 0.5
and 0.9 endotoxin units (EU)/ml.
Immunization and challenge. BALB/c mice (n 5) were immunized
in two independent experiments either with two intramuscular doses (in
the tibialis anterior muscle with the dose split between two legs) of 100g
plasmid DNA and one intraperitoneal dose of 10 g recombinant
protein formulated 50:50 in Alhydrogel (Brenntag Biosector, Den-
mark) or with three subcutaneous doses of a pool of 20 synthetic
peptides (29.5 g/peptide/dose, 10% DMSO) formulated with 12 g
AbISCO100 (Isconova, Sweden) at three weekly intervals.
Mice administered an empty pVR1020 prime followed by a 50:50
alum–1 PBS boost were used as a control group for DNA/protein-vac-
cinated mice, and mice vaccinated with adjuvant AbISCO100 only were
used as a control group for peptide/adjuvant-vaccinated mice. In addi-
tion, each experiment included a group of naive no-vaccine mice for im-
munogenicity assays and evaluation of protective capacity.
Two weeks after the last immunization, mice were challenged with
either 103 cryopreserved sporozoites in 1% mouse serum or 103 pRBC in
PBS in a volume of 200 l intravenously in the tail vein. The sporozoite
dose was based on counts conducted at vialing; the pRBC dose was deter-
mined immediately prior to infection. The process of cryopreservation is
associated with a loss of sporozoite viability, and our challenge dose of 103
cryopreserved sporozoites corresponds to a challenge dose of approxi-
mately 140 freshly dissected sporozoites (56). We have previously estab-
lished that 100% of mice inoculated with as few as 50 cryopreserved P.
yoelii sporozoites developed blood-stage parasitemia (S. Schussek, sub-
mitted for publication). Infectivity controls (nonimmunized naive mice
challenged with parasites in parallel to the test groups) were included in all
experiments, and all developed blood-stage parasitemia from day 4 after
sporozoite challenge (data not presented).
Assessment of liver-stage parasite burden via qRT-PCR. Livers were
harvested at 42 h after challenge and homogenized in 5 ml RNeasy lysis
buffer (RLT; Qiagen Pty Ltd., Chadstone Centre, VIC, Australia) with 1%

-2-mercaptoethanol (Sigma-Aldrich Co LLC., St. Louis, MO, USA).
RNA was extracted from 200 l homogenate using the Qiagen RNeasy
Minikit (Qiagen Pty Ltd.) according to the manufacturer’s instructions.
cDNA was synthesized from 2 g RNA using Vilo reverse transcriptase
(Life Technologies Pty Ltd., Applied Biosystems, Mulgrave, VIC, Austra-
lia) according to the manufacturer’s instructions. cDNA synthesis reac-
tion mixtures were assembled in 20 l on ice and then incubated for 10
min at room temperature, followed by 2 h at 42°C. Reactions were termi-
nated by heating the sample to 85°C for 5 min. cDNA samples were stored
at20°C. P. yoelii 18S cDNA was quantified using a newly developed and
highly sensitive quantitative reverse transcription-PCR (qRT-PCR) assay
(Schussek et al., submitted) modified from a previously described proto-
col (57) and using a custom-made TaqMan probe and primers (Applied
Biosystems) and TaqMan Fast Advanced Master Mix (Applied Biosys-
tems, Life Technologies Australia). The mouse 
2-microglobulin gene
was used as the housekeeping gene (Applied Biosystems kit, at 1/100) to
normalize 18S cDNA threshold cycle (CT) values for analysis. Both P.
yoelii 18S and 
2-microglobulin cDNAs were quantified using a standard
curve of cloned cDNA, and the ratio of P. yoelii 18S cDNA to total mouse
cDNA (
2-microglobulin) was calculated and normalized against values
for the no-vaccine control group to give the percentage of reduction of
liver parasite burden (Microsoft Excel 2007, version 12; Microsoft Corpo-
ration, Redmond, WA, USA).
Assessment of blood-stage parasitemia via flow cytometric assess-
ment of blood (FCAB assay). The kinetics and burden of blood-stage
infection were monitored daily from day 3 to day 14 and 3 times a week
from day 14 to day 30 after either sporozoite or pRBC challenge, by flow
cytometric assessment of the blood as described previously (51). Briefly, 3
l blood was collected from the tip of the tail and diluted into 1 ml FCAB
buffer. Then, 30 l of diluted blood was transferred into a 96-well V-bot-
tom plate (Sarstedt Australia Pty Ltd., Mawson Lakes, SA, Australia), and
cells were fixed for 10 min at 37°C with 4% (wt/vol) paraformaldehyde
and 0.0067% (wt/vol) saponin (Sigma-Aldrich Co., St. Louis, MO, USA).
The parasite nucleic acid was stained with DAPI (4=,6=-diamidino-2-phe-
nylindole) (1g/ml in FCAB buffer) for 30 min at 4°C, and the percentage
of fluorescent cells was measured by flow cytometry on a high-throughput
sampler (HTS)-equipped FACSCanto II (BD Biosciences, San Jose, CA).
Data were analyzed using FlowJo software version 9.1 (Treestar Inc., Ash-
land, OR, USA) and displayed as comparative area under the curve
(AUC): the percentage of parasitized RBCs was measured at multiple time
points over the course of infection (daily from day 3 to day 14 after chal-
lenge and then twice a week until day 30 after challenge), and the curve
determined by the percentage of pRBC over time was analyzed for immu-
nized and control groups. The AUC of blood-stage parasitemia over time
was calculated in order to take into consideration the kinetics of develop-
ment of blood-stage parasitemia and subsequent recovery in immunized
and control groups. In order to compare different experiments, the AUC
values for immunized mice were normalized to the AUC values for no-
vaccine controls of the same experiment that received the same challenge
dose.
T cell assays. Spleens and draining lymph nodes (DLNs) of immu-
nized and unimmunized mice were harvested at the time of challenge (10
to 14 days after the third immunization) and restimulated with PyAMA-1
DNA or peptide pools using A20 cells (mouse B lymphocyte cell line,
ATCC TIB-208) as antigen-presenting cells (APCs). Briefly, A20 cells were
preincubated with 5 g/ml PyAMA-1 peptide pool or transfected with
PyAMA-1 plasmid DNA (5 g DNA/5  106 cells) using the AMAXA
Nucleofector system (kit V; Lonza Group, Basel, Switzerland) according
to the manufacturer’s instructions and then irradiated with approxi-
mately 16,666 cGy (Cs-137 irradiator). Splenocytes and lymph node cells
were harvested by passing the organs through a 70-m cell strainer, fol-
lowed by RBC lysis. Then, 5  105 splenocytes or lymph node cells/well
were coincubated with 1.5 105 antigen-presenting A20 cells/well at 37°C
for 6 h (for intracellular cytokine staining [ICS]) or 48 h (for enzyme-
linked immunosorbent spot [ELISpot] assay and cytokine bead array
[CBA]). These restimulation times and conditions were previously opti-
mized for the induction of cytokine responses using each of the above-
mentioned assays. Mock-stimulated cells, coincubated with irradiated
A20 cells not presenting any antigen, were included for each group of
immunized mice.
(i) IFN- ELISpot assay. The IFN- ELISpot assay was performed
essentially as previously described (58, 59). A total of 5 105 splenocytes/
well in Dulbecco’s modified Eagle’s medium/High Modified dry powder
(KDMEM) (SAFC Global, St. Louis, MO) (6 mg/liter folic acid, 36 mg/
liter L-asparagine, 116 mg/liter L-arginine, 2 g/liter sodium bicarbonate,
10 mM HEPES, 60 mg/liter penicillin, 100 mg/liter streptomycin), 10%
FCS, 5 nM 
-2-mercaptoethanol, and 1.5 mM L-glutamine were plated at
100 l/well into 96-well MultiScreen filter plates (Millipore MAIPS4510
plates) precoated with 100 g/ml anti-mouse IFN- monoclonal anti-
body (MAb) (BD Biosciences, San Jose, CA). Irradiated peptide-pulsed or
antigen-transfected A20 APCs or mitogen control (concanavalin A) was
added at 100 l/well. After incubation at 37°C with 5% CO2 for 36 h,
plates were washed 6 times with 1PBS plus 0.05% Tween 20 (PBST) and
incubated with 25 g/ml biotinylated anti-mouse IFN- antibody (BD
Biosciences, San Jose, CA) for 3 h at 37°C. Plates were again washed and
incubated with 1 g/ml streptavidin-horseradish peroxidase (HRP) (BD
Biosciences, San Jose, CA) for 1 h at room temperature. Plates were then
washed 3 times with PBST and 3 times with PBS, incubated with 3-amino-
9-ethylcarbazole (AEC) substrate solution (BD Biosciences, San Jose, CA)
for 5 min, flooded with tap water to stop the reaction, and dried overnight.
Spot-forming cells (SFCs) were counted using the AID ELISpot reader
Schussek et al.
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(AID ELISpot reader classic; AID, San Diego, CA). Data were analyzed
using Prism 4.02 software (GraphPad, San Diego, CA).
(ii) Cytokine bead array (CBA). A total of 5 105 splenocytes and/or
lymph node cells/well were restimulated with 1.5  105 A20 antigen-
presenting cells (APCs)/well in a total volume of 200l in 96-well round-
bottom plates. After incubation for 48 h at 37°C with 5% CO2, the cell
supernatant was collected for comprehensive analysis of secreted cyto-
kines (IL-1
, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IFN-, and tumor
necrosis factor [TNF]) using the mouse cytometric bead array flex kit (BD
Biosciences, San Jose, CA). Briefly, a mix of capture and detection beads
for each cytokine was incubated with 5l sample for 2 h at room temper-
ature. The fluorescence intensity of the detection beads was measured on
a FACSArray instrument (BD Biosciences, San Jose, CA) and analyzed
using FlowJo software.
(iii) Intracellular cytokine staining (ICS) and analysis ofmultifunc-
tional T cell populations. Splenocytes and/or lymph node cells were re-
stimulated as described for CBA for 6 h and incubated with 0.1% Golgi
Plug (BD Biosciences, San Jose, CA) from the start of the restimulation
period at 37°C with 5% CO2 in 96-well V-shaped plates. Cells were spun at
600 RCF for 4 min, washed with FCAB buffer, and stained for surface
molecules CD4 (mCD4-peridinin chlorophyll protein [PerCP]/Cy5; In-
vitrogen) and CD8 (mCD8-fluorescein isothiocyanate [FITC]; Bioleg-
end) for 30 min at 4°C. Cells were then washed as before and fixed with 1%
paraformaldehyde for 15 min at room temperature. Cells were washed
again and stained for intracellular cytokines IL-2 (mIL-2–phycoerythrin
[PE]; Biolegend), IFN- (mIFN-–allophycocyanin [APC]; Miltenyi Biotec),
and TNF (mTNF-PE/Cy7; Bioscience) overnight at 4°C in the dark. Samples
were acquired on an HTS-equipped FACSCanto II using FACS-DiVa soft-
ware (BD Bioscience).
The percentage of IFN--, IL-2-, or TNF-positive CD4 and CD8
splenocyte populations was calculated by subtracting the unstimulated
background control value from the PyAMA-1-restimulated sample using
Overton subtraction in the FlowJo Population Comparison tool (FlowJo
software version 9.1; Treestar Inc.). To differentiate the percentages of
cells positive for one, any two, or all three of the measured cytokines,
Boolean gates (FlowJo software version 9.1; Treestar Inc.) were created for
IFN--, IL-2-, or TNF-producing CD4 and CD8 T cell populations.
The background frequencies of cytokine-producing populations in un-
stimulated controls were subtracted using the Pestle program v1.6, and
thresholding, visualization, and statistical analysis of data were performed
using SPICE software v5.1 (http://exon.niaid.nih.gov/spice/) (60). The
median fluorescence intensity (MFI) of the three cytokines in single-,
double-, or triple-positive T cell populations relates to the amount of
cytokine secreted from each of these populations. By multiplying the fre-
quency of a multifunctional T cell population by the MFI of the individual
cytokines for this population, the integrated MFI (iMFI) was calculated as
an indicator of T cell functionality (61).
Indirect fluorescent-antibody test (IFAT) by flow cytometry. The
antiparasite antibody titer was determined by flow cytometry as described
previously (62) (see Fig. S1 in the supplemental material). Briefly, sera of
immunized and unimmunized mice were collected 2 weeks after each
immunization and 21 days after challenge, and 30 l of serum diluted in
FCAB buffer (1/100 prechallenge and 1/300 postchallenge) was incubated
with 6 l of parasite extract for 20 min at room temperature. Antibodies
binding to the P. yoelii parasite extract were stained with secondary goat
anti-mouse IgG-DyLight 405 (Biolegend) or a mix of anti-mouse IgG1-
APC (clone A85-1), anti-IgG2a–FITC (clone R19-15), anti-IgM–PE/Cy7
(clone R6-60.2), and anti-IgE–PE (clone RME-1) (all from BD Biosci-
ences) for 15 min at 4°C. Following another wash, the samples were re-
suspended in 35 l of FCAB buffer and analyzed on an HTS-equipped
FACSCanto II. Postacquisition data analysis was performed with FlowJo
software (see Fig. S1 in the supplemental material). All calculations were
performed using Microsoft Excel.
Statistical analysis. Geometric mean responses were calculated and
the nonparametric, two-tailed Mann-Whitney test (Prism 4.02 software
package; GraphPad, San Diego, CA) performed to compare PyAMA-1
immunization groups with control groups. The mean background cyto-
kine response induced by mock stimulation with APC alone in each group
was subtracted from the mean values for restimulated cells. To compare
separate time points or cell populations, we analyzed the difference (cal-
culated as a ratio) between two measurements of the same sample and
evaluated the statistical significance of differences between immunized
and control groups using the two-tailed Mann-Whitney test. Compari-
sons of multiple different stimulations (e.g., with individual peptides)
were evaluated by one-way analysis of variance (ANOVA) followed by
two-tailed Mann-Whitney test. Statistical analysis of multifunctional T
cell populations was conducted using Pestle program v1.6 and SPICE
software v5.1 (60). Significance was defined at the 5% level.
RESULTS
Protective capacity. The primary outcome of the proposed study
was to determine whether PyAMA-1-specific immune responses
could reduce the liver-stage parasite burden or blood-stage para-
sitemia following sporozoite challenge, in order to evaluate
AMA-1 as a target of sterile disease-preventing immune re-
sponses. To address this question, BALB/c mice were immunized
with PyAMA-1 using DNA/protein or peptide/adjuvant ap-
proaches and challenged with 103 infectious P. yoelii 17XNL
sporozoites or 103 parasitized red blood cells (pRBC). The parasite
burdens in liver and blood were assessed by quantitative real-time
PCR (qRT-PCR) or flow cytometric assessment of blood (FCAB),
respectively, and compared to those in control mice.
(i) Liver-stage parasite burden following sporozoite chal-
lenge. Immunization with either DNA/protein or pooled peptide
epitopes in adjuvant significantly reduced parasite burden in the
liver following sporozoite challenge, (Fig. 1A) as determined by
qRT-PCR. The liver-stage parasite burden was reduced by 95.1%
(mean; standard deviation [SD]  2.9) in mice immunized with
PyAMA-1 DNA/protein compared to no-vaccine controls (Fig.
1A) (P  0.0195) and by 51.6% (mean; SD  27.5) in mice im-
munized with PyAMA-1 peptide/adjuvant compared to the adju-
vant-only controls (Fig. 1A) (P 0.0119).
(ii) Blood-stage parasitemia following sporozoite or pRBC
challenge. In parallel groups, mice challenged with infectious
sporozoites (preerythrocytic stage) or pRBC (blood stage) were
monitored for development of blood-stage parasitemia via the
FCAB assay (51). To investigate the effect of AMA-1 immuniza-
tion on the entire course of infection, we calculated the AUC of
blood-stage parasitemia over time and normalized AUC values of
immunized mice to AUC values of control mice challenged at the
same time.
Sterile protection against sporozoite challenge as indicated by
the complete absence of blood-stage parasitemia was observed in
80% of mice immunized with PyAMA-1 DNA/protein (P 
0.0159). In the remaining 20%, blood-stage parasitemia was re-
duced by 65%, indicating partial protection against sporozoite
challenge. However, there was no significant protection against
the development of blood-stage parasitemia in mice immunized
with the PyAMA-1 peptide pool (Fig. 1B).
Neither PyAMA-1 plasmid DNA/protein nor peptide/adju-
vant immunization conferred protection against blood-stage
challenge (Fig. 1C).
Our data demonstrate robust PyAMA-1-induced protection at
the preerythrocytic stage following sporozoite challenge, as evi-
denced by a 98% reduction in liver-stage parasite burden and
sterile immunity in 80% of mice (absence of parasitemia) follow-
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ing DNA/protein immunization. These data establish AMA-1 as a
key target of preerythrocytic-stage immunity.
Immunological response. To obtain information on the un-
derlying immune responses mediating AMA-1-induced protec-
tion against sporozoite challenge, we analyzed cellular immune
responses against the whole antigen or defined CD4 or CD8 T
cell epitopes and measured antibody responses against whole par-
asite.
(i) Cellular responses. Protection against preerythrocytic-
stage malaria (directed at the parasite-infected hepatocyte) is
thought to be mediated mainly by CD8 T cells and Th1-type
CD4 T cells producing IFN-, IL-2, and TNF (13). Thus, we
measured IFN-, IL-2, and TNF production by splenocytes from
AMA-1-immunized mice via ELISpot assay, intracellular cytokine
staining (ICS), and cytokine bead array (CBA). Recent studies
suggest that cells expressing more than one cytokine have better
effector function than single-cytokine-expressing cells and might
correlate with protection against infections requiring T cells (38,
61, 63). Furthermore, T cells expressing more than one cytokine
simultaneously might have a higher capacity to develop into
memory cells (61). Thus, we also analyzed our ICS data in terms of
simultaneous production of any two or all three Th1 cytokines,
IFN-, IL-2, and TNF. Additionally, we investigated the extended
cytokine profile induced by each immunization regime by analyz-
ing the supernatants of splenocytes and lymph node cells after in
vitro restimulation with PyAMA-1 for a panel of 10 cytokines
(IFN-, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-1
, and
TNF) using CBA.
(a) Th1 type cytokines IFN-, IL-2, and TNF. PyAMA-1
DNA/protein immunization increased the number of IFN--ex-
pressing CD4 and CD8 splenocytes compared to those for no-
vaccine controls as measured by ELISpot assay (2-fold [not signif-
icant]), ICS (CD4, 2-fold [P  0.0201]; CD8, 7.8-fold [P 	
0.0001]), and CBA (1.6-fold [P  0.0159]) after restimulation
with PyAMA-1 in vitro (Fig. 2). The percentage of IL-2-positive
CD8 T cells (4.6-fold [P 	 0.0001]) as well as TNF-expressing
CD4 (7.1-fold [P	 0.0001]) and CD8 (6.3-fold [P 0.0002])
T cells was also increased in PyAMA-1 DNA/protein immunized
mice compared to no-vaccine controls, as measured by ICS. No-
tably, Th1 cytokines were preferentially secreted by CD8 T cells
compared to CD4 T cells for all three cytokines (IFN-, P 
0.0079; IL-2, P 0.0079; TNF, P 0.0119) (Fig. 2B; see Fig. S2 in
the supplemental material). PyAMA-1 peptide immunization in-
duced a significant 5-fold increase in IFN- spot-forming cells as
measured by ELISpot assay (P  0.0079) (Fig. 2A), significantly
higher frequencies of IFN- expressing CD8 T cells (6.1 [P 	
0.0001) as measured by ICS, and a significant increase of IFN-
secretion as detected by CBA in spleens (2.5-fold [P 0.0119) but
not lymph nodes of immunized mice compared to values for con-
trols given adjuvant only (Fig. 2B and C). IL-2-expressing CD4
(3.5-fold [P  0.0005]) and CD8 (3.7-fold [P  0.002]) T cells
were also increased in immunized compared to no-vaccine con-
trol mice in the ICS assay, and increased secretion of IL-2 from
spleens (3.9-fold [P  0.0120]) was detected by CBA. However,
TNF was only marginally increased in ICS as well as CBA assays in
both T cell populations and both tissues, respectively. As noted for
DNA/protein immunization, there were significantly more IFN-
-, IL-2-, or TNF-expressing CD8 T cells than CD4 T cells
(IFN-, P 0.0079; IL-2, P 0.0119; TNF, P 0.0117) (Fig. 3C;
see Fig. S2 in the supplemental material) in spleen samples of
AMA-1 peptide/adjuvant-immunized mice.
Overall these data show that both PyAMA-1 immunization
strategies induced robust Th1 cytokine responses, although there
was some inconsistency in the fine details of the response as noted
by us (50) and others (64) previously. The antigen-specific IFN-
response as detected by ELISpot assay and CBA was lower in
PyAMA-1 DNA/protein-immunized mice than in peptide/adju-
vant-immunized mice, but similar levels of IFN-were measured
in splenocytes of both immunized groups by ICS. Both immuni-
zation strategies also induced antigen-specific TNF responses, al-
though the TNF response was higher in DNA/protein-immunized
mice than in peptide/adjuvant-immunized mice when measured
FIG 1 Protective capacity of PyAMA-1 plasmid DNA prime/protein boost immunization and peptide/adjuvant immunization. Mice (n 5/group, represen-
tative of two independent experiments) were immunized 3 times at 3 weekly intervals with plasmid DNA encoding PyAMA-1 and boosted with PyAMA-1 protein
or with PyAMA-1 pools of predicted PyAMA-1 T cell epitopes formulated in AbISCO adjuvant. Mice were challenged at 14 days after the last immunization with
1,000 P. yoelii sporozoites or 1,000 pRBC. Protection was assessed by quantitative RT-PCR (qRT-PCR) and FCAB assay. (A) qRT-PCR of Py18S rRNA in total
liver RNA 42 h after sporozoite challenge, normalized against the parasite liver burden in infectivity control mice immunized with empty vector. (B) Parasitemia
in the blood measured as area under the curve (AUC) after sporozoite challenge, normalized against the AUC for infected empty vector control-immunized mice.
(C) Parasitemia in the blood (AUC) after blood-stage challenge, normalized against the AUC for infectivity control mice immunized with empty vector.
Statistical analysis was conducted by a two-tailed Mann-Whitney test; significance was defined as a P value of	 0.05. n.s., not significant.
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by ICS (CD8 T cells, P  0.0071; CD4 T cells, P  0.0007).
Furthermore, the robust antigen-specific IL-2 responses induced
by either PyAMA-1 DNA/protein or PyAMA-1 peptide/adjuvant
immunization detected by ICS were not measurable in the CBA.
Consistent with a role for CD8 T cells in preerythrocytic-stage
immunity, PyAMA-1-specific CD8 responses were more pro-
nounced than CD4 responses in both immunized groups (Fig. 2;
see Fig. S2 in the supplemental material).
(b) Multifunctional T cells. The relative distribution of the
different CD4 and CD8 T cell populations expressing every
possible combination of IFN-, IL-2, and TNF following
PyAMA-1 immunization was significantly different from the rel-
ative distribution of those populations in no-vaccine control mice
for DNA/protein (CD4, P  0.0176; CD8, P  0.0047) and
peptide/adjuvant (CD4, P 0.0059; CD8, P 0.0068) immu-
nization (Fig. 3A).
The number of IFN-/IL-2/TNF triple-positive T cells was sig-
nificantly increased for CD4 and CD8 T cell populations ex-
tracted from spleens of PyAMA-1 DNA/protein-immunized mice
compared to no-vaccine controls (CD4, 20% [P  0.018];
CD8, 25% [P  0.05]) (Fig. 3A and B). Additionally, the per-
centage of IFN-/IL-2 double-positive CD4 and IL-2/TNF dou-
ble-positive CD4 and CD8 T cells was increased in PyAMA-1
DNA/protein-immunized mice compared to no-vaccine controls
(CD4 IFN-/IL-2, 20% [P  0.018]; CD4 and CD8 IL-2/
TNF, 18% and 33%, respectively [P 0.018]) (Fig. 3).
Consistent with the profile measured following DNA/protein
immunization, multifunctional CD4 T cell populations were
also significantly higher in PyAMA-1 peptide/adjuvant-immu-
nized mice than in adjuvant-only controls (triple positive, 10%
[P 0.018]; double-positive IFN-/IL-2 and IL-2/TNF, 14% and
17.5%, respectively [P 0.018]) (Fig. 3C). However, and in con-
trast to the case for PyAMA-1 DNA/protein immunization,
PyAMA-1 peptide/adjuvant immunization was very poor in in-
ducing a multifunctional CD8 T cell population (Fig. 3D); only
the IL-2/TNF double-positive CD8 T cell population was signif-
icantly greater in PyAMA-1 peptide/adjuvant-immunized mice
than in adjuvant-only controls (33.5% [P 0.018]).
The amount of cytokine expressed in multifunctional T cells
was generally higher than that in single-cytokine-producing cells
following PyAMA-1 DNA/protein immunization, as evidenced by
the iMFI (Fig. 4A). Triple-positive CD4 and CD8 T cell popu-
lations accounted for 29.5% and 37.8%, respectively, of the total
IFN- expression (Fig. 4A), and within the total populations of
IL-2- and TNF-expressing CD8 T cells, 61% and 39.5%, respec-
tively, were triple positive (Fig. 4A). Similarly, IL-2 and TNF ex-
pression in double-positive CD4 (45% of total IL-2 and 56.2% of
total TNF) and double-positive CD8 (36.4% of total IL-2 and
59.1% of total TNF) T cells was increased compared to that in
single-cytokine-expressing T cell populations after PyAMA-1
DNA/protein immunization (Fig. 4A). However, and consistent
with an increase in the frequency of IFN--expressing CD4 T
cells compared to that in no-vaccine controls (17.5%; P 0.018)
(Fig. 3B), IFN- single-positive cells comprised approximately
48.4% and 33.6% of the CD4 and CD8 T cell populations,
respectively (Fig. 4A).
In contrast, following immunization with PyAMA-1 peptide/
adjuvant, the highest contribution to IFN- and TNF expression
FIG 2 IFN-, IL-2, and TNF responses at the time of challenge. (A) IFN- ELISpot assay of splenocytes restimulated in vitro with the PyAMA-1 peptide pool for
36 h. (B) Intracellular cytokine staining for IFN-, IL-2, and TNF for CD4 (white bars) and CD8 (black bars) cell populations after DNA/protein immuni-
zation (I) or peptide/adjuvant immunization (II) and restimulation for 6 h. Data were analyzed using FACS-DiVa software and the FlowJo population
comparison tool. (C) CBA for IFN-, IL-2, and TNF secretion of splenocytes after restimulation with PyAMA-1 for 48 h. ELISpot data (SFC/million splenocytes)
are presented as individual data points for 5 mice (representative of two independent experiments; n 10). ICS (percent cytokine expression) and CBA (pg/ml
secreted cytokine after correction for background in empty vector control groups) data are represented as the mean value (n  10 mice, two independent
experiments). Statistical significance compared to no-vaccine or adjuvant-only controls was determined by a two-tailed Mann-Whitney test (***, P	 0.0005; **,
P	 0.005; *, P	 0.05).
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FIG 3 Multifunctional T cell responses induced by PyAMA-1 immunization. (A) The distribution of triple-cytokine-positive (red), double-cytokine-positive
(orange), single-cytokine-positive (blue), and cytokine-negative (gray) T cell populations for PyAMA-1-immunized and control mice is presented as pie charts.
Statistical evaluation of pie charts was done using a permutation test, comparing each distribution against the respective control group; significance was defined
as a P value of	 0.05. (B to E) A comparison of splenic PyAMA-1-specific production of IFN-, TNF, and IL-2 in immunized (black) versus control (gray) mice
in CD4T cells (B) and CD8T cells (C) of DNA/protein-immunized or CD4T cells (D) and CD8T cells (E) of peptide/adjuvant-immunized mice, assessed
at the time of challenge as described in the legend to Fig. 1. Data are presented as relative frequency for each population after correction for background cytokine
production in unstimulated cells, conducted using Pestle program v1.6 and SPICE software v5.1. The statistical significance of results for immunized versus
control groups was determined using the Wilcoxon rank test (*, P	 0.05).
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was made by single-positive CD4 T cells (IFN-, 92.2%; IL-2,
88.7%; TNF, 83.5%) and CD8 T cells (IFN-, 61.3%; IL-2,
87.2%; TNF, 68.4%) rather than multifunctional cells (Fig. 4B).
Very low levels of cytokines were expressed in triple-positive and
double-positive CD4 T cells (Fig. 4B). Consistent with the
above-noted increase in the frequency of IL-2/TNF double-posi-
tive CD8 T cells compared to that in adjuvant-only controls,
87.2% of the total IL-2 and 31.6% of the total TNF were produced
by double-positive CD8 T cells (Fig. 4B).
Overall, PyAMA-1 DNA/protein immunization, but not pep-
tide/adjuvant immunization, induced robust multifunctional
CD4 and CD8 T cell responses with a preference toward high
triple-positive and IL-2/TNF double-positive CD8 T cell re-
sponses.
(c) Other cytokine responses. Using CBA, we measured the
quantities of IL-12p70, IL-1
, IL-6, IL-13, IL-4, IL-5, and IL-10
secreted in the supernatant of splenocytes from PyAMA-1-immu-
nized mice restimulated in vitro with full-length PyAMA-1 or a
PyAMA-1 peptide pool for 48 h. To provide additional informa-
tion on the PyAMA-1-specific cellular responses, we also profiled
cytokine secretion by cells harvested from the draining lymph
nodes.
Significant levels of IL-4 and IL-5 were detected in both spleno-
cytes and lymph nodes of mice immunized with peptide/adjuvant
(for IL-4, spleen P 0.0347 and DLN P 0.0317; for IL-5, spleen
P 0.0195 and DLN P 0.0159) but not DNA/protein (Fig. 5).
IL-4 secretion was significantly higher (23.2-fold; P	 0.0001) in
the spleens than in the lymph nodes of PyAMA-1 peptide/adju-
vant-immunized mice (Fig. 5B) and significantly higher in spleno-
cytes of PyAMA-1 peptide/adjuvant- than DNA/protein-immu-
nized mice (93-fold; P  0.0001) (Fig. 5A). Significant levels of
IL-12 and IL-13 were also detected in lymph nodes (IL-12, P 
0.0079; IL-13, P  0.0286) but not spleens of peptide/adjuvant-
immunized mice (Fig. 5B). All other measured cytokine responses
were marginal.
(ii) Identification of immunodominant epitopes. The robust
IFN- responses induced in our studies as reported above pro-
vided the opportunity to identify, for the first time, minimal
CD4 and CD8T cell epitopes on PyAMA-1. Understanding the
IFN- response to the different immunization strategies could
also allow us to identify differences in the immunodominant
epitopes recognized. Indeed, we identified robust IFN- responses to
five peptides of the pool of 20 putative T cell epitopes (15 CD8
and 5 CD4 peptides predicted to bind with high affinity to MHC
class I or II molecules) in mice immunized with PyAMA-1 pep-
tide/adjuvant (Fig. 6 and Table 1). Four of these five immuno-
dominant PyAMA-1 epitopes are MHC class I specific (H-2Kd
peptide I-1, H-2Dd peptide I-10, H-2Kd peptide I-3, and H-2Dd
peptide I-6), and one is MHC class II specific (H-2 IAd peptide
II-4), indicating a CD8 T cell bias for the peptide immunization.
FIG 4 IFN-, IL-2, and TNF production induced by PyAMA-1 immunization. The contributions of different CD4 and CD8 T cell populations to total
cytokine production are illustrated in pie charts based on the integrated median fluorescence intensity (iMFI), calculated by multiplying the frequency of cells
producing a given cytokine by the magnitude of the cytokine response (measured as median fluorescence intensity). (A) iMFI of splenocytes after PyAMA-1
DNA/protein immunization; (B) iMFI of splenocytes after peptide/adjuvant immunization.
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A dominance hierarchy was noted, with two of the epitopes (H-
2Kd peptide I-1 and H-2Dd peptide I-10) recognized by similar
numbers of IFN- secreting cells as the complete peptide pool
(Fig. 6).
The IFN- response to individual peptides following DNA/
protein immunization was much less robust than that following
peptide/adjuvant immunization. Nevertheless, we were able to
identify one H-2Kd binding peptide (I-2) and three H-2Dd bind-
ing peptides (I-7, I-13, and I-15) that were recognized by a 2-fold-
higher number of cells compared to controls (Table 1; see Fig. S3
in the supplemental material); these responses were not signifi-
cantly different from the background and did not overlap the
epitopes identified following peptide immunization (Table 1).
Additional studies are necessary to establish whether or not these
peptides are also targets of PyAMA-1-specific CD4 or CD8 T
cell responses.
Since polymorphism in parasite epitopes targeted by host im-
mune responses is problematic for vaccine development (65), we
next analyzed the polymorphism of the identified immunodomi-
nant epitopes. Surprisingly, given that AMA-1 is highly polymor-
phic (1), all five immunodominant PyAMA-1 epitopes identified
in our studies were highly conserved (66%) across rodent spe-
cies (Table 1 and Fig. 7A and B), and two of the five epitopes (I-3
and II-4) showed high levels of conservation across all animal and
human species (59 to 88%) (Fig. 7A and B and Table 1).
Two of the five newly identified epitopes (I-6 and I-10) overlap
peptide sequences shown to be recognized by malaria-exposed
adults in Kenya (66) (PL186 in 25% of peripheral blood mononu-
clear cell [PBMC] donors and PL192 in 18% of PBMC donors,
respectively), and a third (I-3) overlaps with cryptic epitopes
shown to be targeted by T helper cells associated with protective
antibodies in P. chabaudi (35). One of the putative epitopes iden-
tified following DNA/protein immunization (I-2) was also iden-
tified in malaria-exposed adults in Kenya (PL190 in 10 to 12% of
PBMC donors) (66), suggesting that this sequence does in fact
represent a true T cell epitope.
(iii) Humoral responses. Antibodies against sporozoite and
merozoite proteins are known to inhibit parasite entry into host
cells, and antibodies against parasite proteins expressed on the
surface of infected hepatocytes or erythrocytes can mediate inhi-
bition of parasite development (13, 15, 67, 68). To determine
whether antibodies could potentially contribute to the observed
reduction of blood-stage parasitemia after sporozoite challenge in
PyAMA-1 DNA/protein-immunized mice, we measured the level
of antibodies binding to whole blood-stage parasites in the sera of
immunized and unimmunized mice before and 23 days after
sporozoite challenge (see Fig. S1 in the supplemental material).
The level of parasite-specific IgG antibody was significantly in-
creased in mice immunized with PyAMA-1 DNA/protein (P 
0.0079) and peptide/adjuvant (P 0.0079) compared to controls
(Fig. 8).
Next, we analyzed IgG subtypes, measuring the levels of
mIgG2a (correlating to human IgG1) and mIgG1 (correlating to
FIG 5 Cytokine bead array analysis of cytokine responses induced by PyAMA-1 immunization. (A) Splenocytes from mice immunized with PyAMA-1
DNA/protein restimulated in vitrowith PyAMA-1 DNA-transfected A20 cells. (B) I, splenocytes from mice immunized with PyAMA-1 peptide pool/AbISCO100
adjuvant restimulated in vitro with PyAMA-1 peptide pool. II, lymph node cells from mice immunized with PyAMA-1 peptide pool/AbISCO100 adjuvant
restimulated in vitro with PyAMA-1 peptide pool. Data are presented in pg/ml after correction for background cytokine production in empty vector or
adjuvant-only controls. Statistical significance compared to controls was determined by a two-tailed Mann-Whitney test (**, P	 0.005; *, P	 0.05).
FIG 6 Immunodominant PyAMA-1 epitopes identified after peptide/adju-
vant immunization. IFN- production by splenocytes harvested from mice
immunized with peptide/adjuvant at 10 days after the third immunization and
restimulated with individual peptides or PyAMA-1 peptide pool in vitro is
shown. Data are presented as mean spot-forming cells (SFCs) for individual
mice (n 5), with error bars representing the total range of values. The dotted
line represents the mean background reactivity of unstimulated cells. Statisti-
cal significance for the mean number of SFCs in restimulated cells compared to
adjuvant-only controls was determined by one-way ANOVA and a two-tailed
Mann-Whitney test (**, P	 0.01; *, P	 0.05).
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human IgG2) in immunized mice before and after challenge (see
Fig. S4 in the supplemental material). The ratio of mIgG2a to
mIgG1 levels postchallenge was significantly (P 0.0278) higher in
DNA/protein-immunized mice than in no-vaccine controls (2.28
0.4 compared to 0.46 0.05), consistent with a bias toward a cyto-
philic antibody response. Neither IgM nor IgE was elevated by
PyAMA-1 immunization compared to control treatment.
DISCUSSION
A number of studies in animal models (summarized in reference
1) confirm that AMA-1 is a target of antibody-mediated protective
immunity against blood-stage Plasmodium parasites. AMA-1 has
thus been considered a high-priority target antigen for a blood-
stage malaria vaccine. However, AMA-1 is also expressed in Plas-
modium sporozoites and liver stages (4, 42, 43) and may therefore
also be a target of protective preerythrocytic-stage immune re-
sponses. A role for AMA-1 in the induction of protective immu-
nity against preerythrocytic Plasmodium stages has not been dem-
onstrated yet. Here, we performed the first evaluation of the
immunogenicity and protective capacity of PyAMA-1 adminis-
tered via DNA prime/protein boost or peptide/adjuvant immuni-
zation strategies against sporozoite challenge and established that
AMA-1 is a target of sterile infection-blocking immune responses
directed at the preerythrocytic parasite stage. As immunodomi-
nant epitopes for AMA-1 have not been previously identified, we
utilized a whole-antigen immunization strategy incorporating
immunization with PyAMA-1 plasmid DNA and recombinant
protein in order to maximize immune responses to all possible
AMA-1 epitopes; DNA/protein strategies have previously proved
successful in inducing protection in animal models of malaria
(69). The PyAMA-1 peptide/adjuvant strategy, on the other hand,
was designed to focus immune responses on putative CD4 and
CD8 T cell epitopes predicted to bind BALB/c MHC class I and
class II molecules with high affinity. We elected to formulate the
pool of predicted peptide epitopes with the adjuvant AbISCO100, a
commercially available ISCOM-matrix formulation consisting of
cholesterol, phospholipid, and a combined structure of two saponin
fractions that has previously described to generate a balanced im-
mune response with both Th1 and Th2 characteristics (70).
In independent experiments, sterile protection assessed as
complete absence of blood-stage parasitemia was induced in 80%
of mice immunized with PyAMA-1 DNA/protein (Fig. 1B). The
TABLE 1 PyAMA-1 immunodominant peptides and their conservation across rodent and primate malaria-causing species
Peptide MHC class Sequence Location (residues)
SFCs/million splenocytesa Conservation (%)b
DNA/protein Peptide Rodent Primate Cross-species
I-1 I YYIFILCSI 5–13   81.5 64.8 54.0
I-3 I QYIAENNDV 455–463   77.8 72.2 58.7
I-6 I EGPNQVISE 23–31   70.4 NA 36.8
I-10 I FTPEKIENY 221–229   74.1 59.3 49.2
II-4 II NDKNFIATTALSSTE 366–380   87.5 76.0 71.1
I-2 I SLCAKHTSL 160–168   77.8 61.1 50.8
I-7 I DKPVRSGGL 118–126   66.7 74.1 52.2
I-13 I AFPETDVHI 127–135   66.7 55.6 52.4
I-15 I GKGYNWGNY 339–347   77.8 72.2 75.7
AMA-1   48.3 54.9 51.6
a IFN- ELISpot response to AMA-1-expressing cells or AMA-1 peptide pool.,100;,50;,25.
b Conservation was determined by CLUSTALW alignment of annotated protein sequences (www.plasmoDB.org) (52) for defined PyAMA-1 peptide sequences (class I or class II) or
full-length AMA-1 protein. The analysis was split into conservation across all rodent species (rodent), conservation across all human and nonhuman primate species (primate), and
conservation across all Plasmodium species (cross-species). NA, not applicable.
FIG 7 Conservation of immunodominant AMA-1 epitopes across Plasmodium species. Immunodominant epitopes were defined by DNA/protein (A) or
peptide/adjuvant (B) immunization. PY01580, P. yoelii; PBANKSA_0900, P. berghei; PCHAS_093100, P. chabaudi; PF11_0344, P. falciparum 3D7;
PFIT_PF_0344, P. falciparum IT; PKH_093110, P. knowlesi; PVX_092275, P. vivax (www.plasmoDB.org) (52). Gray, conserved across two rodent Plasmodium
species; dark turquoise, conserved across two human species; light turquoise, conserved across four animal and human species.
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liver-stage parasite burden, as assessed by quantitative RT-PCR,
was reduced by 95.1% (mean; SD 2.9) in mice immunized with
PyAMA-1 DNA/protein compared to infected control groups.
Immunization with the selected pool of putative PyAMA-1 T cell
epitopes in adjuvant was less efficient and more variable but none-
theless resulted in a 51.6% reduction in liver-stage parasite burden
(mean; SD 27.5) (Fig. 1A). This difference in outcome is likely
due to the presence of additional epitopes within the whole anti-
gen sequence. An alternative explanation would be underlying
differences in uptake and presentation of PyAMA-1 by antigen-
presenting cells and subsequent priming of PyAMA-1-specific T
cells (71). Additional studies evaluating additional minimal T cell
epitopes, longer peptides, or different peptide formulations might
improve a PyAMA-1 peptide-based immunization strategy.
In parallel to protection studies, we also evaluated the fine
specificities of the PyAMA-1 DNA/protein- and peptide/adju-
vant-induced immune responses. Although there are no estab-
lished correlates of protective immunity against malaria, protec-
tion at the liver stage is thought to be mediated primarily by CD8
T cells, with a role for CD4 T cells, and production of Th1-type
cytokines (13, 67). IFN- is routinely used as surrogate marker for
preerythrocytic-stage immunity (72). Studies comparing malaria-
specific cytokine profiles of protected and unprotected individuals
and their capacity for inhibition of the development of early par-
asite stages confirmed the importance of IFN- for protection but
also established TNF as mediator of inhibition of preerythrocytic
development (73–78). In accordance with these findings, we
found that levels of IFN- and TNF were significantly elevated in
mice receiving the protective PyAMA-1 DNA/protein vaccine
compared to unprotected mice (Fig. 2 and 5).
However, T cell cytokine responses induced by immunization
are highly heterogeneous, and an imbalance of proinflammatory
cytokines (such as IFN- and TNF) has been strongly associated
with pathogenesis caused by infectious agents (28, 79–81). Also,
differences in the types of cytokines produced by individual cells
have profound implications for their capacity to mediate protec-
tive effector function and/or be sustained as memory cells (61).
Thus, multifunctional T cells secreting more than one cytokine,
especially IFN-, IL-2, and TNF, have recently been suggested as
better correlated with protection than single-cytokine-producing
cells (61, 82–84).
In our studies, the frequencies of triple-positive (IFN-/IL-2/
TNF) CD4 T cells and double-positive (TNF/IL-2) CD4 and
CD8 T cells were significantly increased after DNA/protein im-
munization compared to those in controls (Fig. 3). Importantly,
we observed that the CD8 T cell response after PyAMA-1 DNA/
protein immunization was significantly more robust than the
CD4 T cell response, with higher frequencies of multifunctional
CD8 T cells and higher magnitudes of cytokines secreted from
triple- or double-positive CD8 T cells than from CD4 T cells
(Fig. 3, Fig. 4). These findings are consistent with a primary role
for CD8 T cells in preerythrocytic immunity.
AMA-1-induced protection against blood-stage Plasmodium
spp. in animal models has been associated with AMA-1-specific
antibodies (1, 21, 23, 35). In our studies, immunization with
PyAMA-1 DNA/protein did induce an antibody response to
blood-stage parasites but failed to protect against P. yoelii 17XNL
blood-stage challenge. Furthermore, levels of antiparasite IgG af-
ter immunization were only poorly boosted by homologous par-
asite challenge. Finally, subtyping studies identified a bias toward
cytophilic antibodies but did not show a preferential induction of
isotypes associated in humans with cellular immunity via ADCI
(85). Taken together, our data support the concept that the robust
PyAMA-1 DNA/protein-induced protection observed in our
studies is directed at the preerythrocytic stages of the parasite and
likely mediated by T cells rather than antibodies, although further
studies are required to define the dependency of AMA-1-induced
protection on specific T cell subsets versus antibodies.
Here, we also report the first identification of minimal CD8
and CD4 T cell epitopes on P. yoelii AMA-1. Specifically, we
identified two immunodominant CD8T cell epitopes at residues
5 to 13 (YYIFILCSI) and residues 221 to 229 (FTPEKIENY) and
two less dominant CD8 T cell epitopes at residues 455 to 463
(QYIAENNDV) and residues 23 to 31 (EGPNQVISE), as well as
an immunodominant CD4 T cell epitope at residues 366 to 380
(NDKNFIATTALSSTE). The regions around YYIFILCSI and EG
PNQVISE overlap two HLA-A-0201 epitopes, one HLA-A-2402
epitope, and two HLA_DRB5*0101 epitopes predicted for the P.
falciparum AMA-1 protein. FTPEKIENY overlaps one HLA-A-
1101 epitope predicted for the P. falciparumAMA-1 protein (D. L.
Doolan and A. Sette, unpublished data). The crystal structure of
the AMA-1 ectodomain shows a conserved central core and vari-
FIG 8 IgG recognition of whole Plasmodium parasite extract. Flow cytometric analysis of total IgG levels binding to P. yoelii blood-stage extract in the sera of
DNA/protein (A)- or peptide/adjuvant (B)-immunized mice at the time of challenge is shown. Data are presented as median fluorescence index (MFI) correlating
to the antibody titer. The dashed lines represent the unspecific IgG response measured in no-vaccine controls, which was used to normalize antibody titers of
immunized and empty vector or adjuvant-only groups. Statistical significance was determined by a two-tailed Mann-Whitney test (P	 0.05).
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able external loops formed by domains I, II, and III (86). The most
polymorphic regions surround a hydrophobic groove containing
cryptic and conserved epitopes (87, 88), but the well-studied in-
hibitory monoclonal antibody 1F9 maps to variable epitopes (89).
Less is known regarding the T cell epitopes of AMA-1 and whether
or not they fall in the region of highest variability. The synthetic
peptides used in our study map to the prosequence as well as
domains I, II, and III of AMA-1, spanning conserved as well as
variable regions. Epitopes I-1 and I-6 map to the signal sequences
and prodomain of AMA-1, whereas epitopes I-10, II-4, and I-3
map to domains I, II, and III, respectively. We establish that all of
these newly identified epitopes are relatively conserved among
Plasmodium strains, suggesting that the corresponding P. falcipa-
rum orthologs may represent immunodominant T cell targets in
P. falciparum. Consistent with this, we noted that two of our newly
identified immunodominant peptides overlap peptides previ-
ously described as targets of proliferative T cells in malaria-ex-
posed adults in Kenya (66).
In summary, here we provide the first demonstration that
AMA-1 is a target of sterile protective immunity against Plasmo-
dium sporozoite challenge, validating the potential of AMA-1 as
an effective target antigen for vaccines directed against preeryth-
rocytic-stage malaria. We identified immunodominant CD8
and CD4 T cell epitopes derived from P. yoelii AMA-1 to facili-
tate preclinical development of such a vaccine, as well as other
more basic research studies. We further established PyAMA-1 as
potent inducer of Th1-type cellular immune responses, in partic-
ular IFN-, TNF, and IL-2, known to be beneficial in immunity
against intracellular pathogens. Finally, we showed that AMA-1
stimulates multifunctional CD8 T cells, which are implicated as
more efficient than single-cytokine-secreting cells in protection
against complex intracellular pathogens such as Plasmodium spp.
These data validate the potential of AMA-1 as a promising target
antigen for vaccines directed against preerythrocytic-stage ma-
laria, as well as for inclusion in multistage malaria vaccines.
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